Piper Jaffray analyst William Quirk says Hologic's updated guidance, following the recent suspension of marketing and distribution of TempSure and MonaLisa Touch product slow down, are "better than expected and speaks to the strength of underlying business." Management reiterated Q4 revenue guidance and stated that it includes a projected Cynosure revenue decline of $15M more than previously guided, Quirk tells investors in a research note. The analyst believes Hologic is "close to turning a corner" and he reiterates an Overweight rating on the shares with a $48 price target.